Meeting
2017 ASCO Annual Meeting
Objective response rate and progression-free survival as surrogate endpoints for overall survival and the impact of crossover and unbalanced post-progression treatments: A systematic review and meta-analysis in first-line therapy of advanced non-small cell lung cancer.
Authors
Boris Pfeiffer
Merck KGaA, Darmstadt, Germany
Boris Pfeiffer , Mahmoud Hashim , Monica Duran , Maarten Postma , Bart Heeg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9049)
DOI
10.1200/JCO.2017.35.15_suppl.9049
Abstract #
9049
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
First Author: Waleed Ikram
Poster
2021 ASCO Annual Meeting
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
First Author: Fang Wu
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A network meta-analysis of immunotherapy-based regimens for first-line treatment of advanced non-squamous non-small cell lung cancer.
First Author: Himani Agg
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Wai Lin Thein